Navigation Links
CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
Date:8/18/2011

the triptan class, which was first launched almost 20 years ago," remarked Thomas P. Mathers, Chief Executive Officer of CoLucid.  "Patient and physician feedback note that only a portion of migraine patients are adequately controlled on triptans, and patients would welcome a new product that could offer a rapid speed of onset, superior pain relief and/or a lack of cardiovascular side effects as compared to currently available products.  In addition, due to their vasoconstrictor activity, triptans are contraindicated in patients with cardiovascular disease.  Many neurologists and primary care physicians feel uncomfortable prescribing triptans because of their potential cardiovascular side effects.  Lasmiditan may address these unmet needs with its novel mechanism of action, and we look forward to the results of the Phase 3 trials to confirm its rapid speed of onset, superior pain relief and lack of cardiovascular side effects," said Mr. Mathers.

The Company is speaking with potential partners and is interacting with the FDA, and plans to advance lasmiditan into Phase 3 development.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.

Media Contact: Kathy Kelly CoLucid Pharmaceuticals, Inc., 919-806-4304, kkelly@colucid.co
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
2. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
3. Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
5. Access Pharmaceuticals Provides Second Quarter Update on MuGard Commercial Activities
6. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
7. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
8. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
9. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
10. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
11. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... fiscal year 2015 financial results after the market close ... will follow on the same day at 4:30 p.m. ... and Chief Executive Officer, and Rick Eiswirth , ...
(Date:7/30/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 6, 2015, at 11:00 AM Eastern Time ... June 30, 2015, and to provide an update on ... via the Maestro® System. Conference Call Details ...
(Date:7/30/2015)... 2015 Tissue Regenix Group ... medical devices company, announces that it has further ... market as Tissue Regenix Wound Care Inc. has ... First Coast Service Options Inc. ("First Coast") whose ... Puerto Rico and the US ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3
... , , , , , , ... MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over,640 ... (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery and development ... that it has completed,the enrolment of the second Phase III trial ...
... , NORCROSS, Ga., Dec. 15 Immucor, Inc. (Nasdaq: ... to the blood transfusion industry, today announced that it will ... 6, 2010 after the market close. The Company will host ... a.m. (Eastern Time) to discuss the results. , ...
Cached Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... at the annual All-Stars Summit. Google Partners is the platform for search marketing ... the full support and tools necessary to run successful search marketing campaigns. Google ...
(Date:7/30/2015)... ... , ... Quintessa Medical Spa is happy to offer patients the latest treatment ... for the elimination of excess tissue under the chin, referred to as submental fat. ... to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was approved by ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American ... Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back Days. The ... from 10:00 AM to 2:00 PM local time. On the 26th, the DEA, ...
(Date:7/30/2015)... Raleigh, NC (PRWEB) , ... July 30, 2015 , ... ... older patients. Click here to read more on the Surviving Mesothelioma website. ... Orthopedic Rehabilitation Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between ...
(Date:7/30/2015)... ... 30, 2015 , ... 1Heart Caregiver Services LLC is offering its 1st Business ... in the Booming Homecare Business.” This will be held in its main headquarters at ... event will be hosted by 1Heart’s very own Randy Clarito (Director of Business and ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
... overeating, slothful horse leads to an obese horse. Unlike humans, ... obese horse. Caretakers may see no harm in giving their ... unhealthy as obesity in humans and can lead to fatal ... humans and horses when it comes to obesity," said Philip ...
... All India Institute of Medical Sciences (AIIMS) has developed ... cancer, underdeveloped genitals.// ,Doctors at the premier ... suffering from such problems, achieving 100 percent success. ... over 50 patients with not a single case of ...
... Divers scouring the sea-bed for abalone are paying with their ... while pursuing abalone, which is used in sushi// and a ... dollars apiece on the black market. ,Abalone are ... this mollusk is considered a delicacy in certain parts of ...
... Gulping down several litres of water to keep oneself cool ... won’t make much difference, warns scientists for marathon runners//. ... average runner will potentially lose almost a litre of sweat ... degrees, two degrees above normal. The sporting community has long ...
... called levodopa or L-dopa that helps in reviving cellular ... may experience motor complications and a reduced response to ... process of destruction of brain cells which produce dopamine. ... up as tremors in the arms, legs and face. ...
... and the possible reasons for them, a survey was ... revealed that present statistics of stillborns remained unchanged upon ... one in 200 pregnancies resulted in stillbirth, the survey ... Health (CEMACH) revealed that there were 3,600 ...
Cached Medicine News:Health News:Humans Aren't the Only Ones With Obesity Problems 2Health News:Artificial Testis Developed by AIIMS a Boon to Suffering Patients 2Health News:Hunt for Sea Delicacy Taking a Toll in California 2Health News:Hunt for Sea Delicacy Taking a Toll in California 3Health News:Large Fluid Intake Won’t Help to Keep Cool for Marathon Runner 2Health News:Stillbirth Figures Stand Still 2
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Manufactured in titanium....
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: